Abstract
This white paper is an assessment of a multi-formulation treatment protocol that is patented to treat Non-Hodgkin Lymphoma (NHL) which is an evaluation of the science behind the potential success of this theory. The patent incorporates specific micronutrients, bioactive phytochemicals, prebiotics, probiotics, and minerals, which are independently informed to a position in standard oncology and immunology literature to affect an action on immune modulation, regulation of oxidative stress, and control of cancer cell signaling. New research indicates that such compounds as curcuminoids, resveratrol, quercetin, vitamin D, zinc, and microbiome-promoting fibers might modify lymphoma-related processes, including tumor-induced apoptosis, tumor inflammation, and microenvironmental control as an adjunctive treatment. The dosing regimen described in the patent is consistent with the pharmacokinetic principles of bioavailability, synergies and immune homeostasis through oncologic stress. The invention is scientifically plausible, integrative in approach, which builds on top of standard NHL solutions, incorporating evidence-based natural compounds in a structured and rational therapeutic plan.
References
- Aggarwal BB, Gupta SC and Sung B. “Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers”. British Journal of Pharmacology 169.8 (2013): 1672-1692.
- Caponio GR., et al. “Nutraceuticals: Focus on anti-inflammatory, anti-cancer, antioxidant properties in gastrointestinal tract”. Antioxidants 11.7 (2022): 1274.
- Calder PC. “Nutrition, immunity and COVID-19”. BMJ Nutrition, Prevention & Health 3.1 (2020): 74.
- Carr AC and Maggini S. “Vitamin C and immune function”. Nutrients 9.11 (2017): 1211.
- Cheson BD., et al. “Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification”. Journal of Clinical Oncology 32.27 (2014): 3059-3067.
- Covarrubias AJ., et al. “NAD+ metabolism and its roles in cellular processes during aging”. Nature Reviews Molecular Cell Biology 22.2 (2021): 119-141.
- Derebas J., et al. “The new treatment methods for non-Hodgkin lymphoma in pediatric patients”. Cancers 14.6 (2022): 1569.
- Derrien M, Alvarez AS and de Vos WM. “The gut microbiota in the first decade of life”. Trends in Microbiology 27.12 (2019): 997-1010.
- Grover M., et al. “Focus on multi-targeted role of curcumin: A boon in therapeutic paradigm”. Environmental Science and Pollution Research 28.15 (2021): 18893-18907.
- Izuegbuna OO. “Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies”. Frontiers in Nutrition 9 (2022): 1008893.
- Mazziotta C., et al. “Probiotics mechanism of action on immune cells and beneficial effects on human health”. Cells 12.1 (2023): 184.
- Potre C., et al. “A systematic review assessing the impact of vitamin D levels on adult patients with lymphoid malignancies”. Current Oncology 30.4 (2023): 4351-4364.
- Raut LS and Chakrabarti PP. “Management of relapsed-refractory diffuse large B cell lymphoma”. South Asian Journal of Cancer 3.1 (2014): 66-70.
- Sun L., et al. “Approaches to modeling cancer metastasis: from bench to bedside”. Frontiers in Oncology 15 (2025): 1602489.
- Yuen RC and Tsao SY. “Embracing cancer immunotherapy with vital micronutrients”. World Journal of Clinical Oncology 12.9 (2021): 712.